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Although breast cancer is a highly preva-
lent disease, breast cancer mortality has
dropped in the United States and Western
Europe in recent years.This improvement
has been attributed to early detection,
optimal use of surgery and radiotherapy,
and use of adjuvant systemic therapy 
like the selective estrogen receptor 
modulator, tamoxifen, and combination
chemotherapy (EBCTCG, 2005). Despite
these advances, women with
a new diagnosis of early
stage breast cancer face
three potential threats: recur-
rence of the original cancer
in the same breast, recur-
rence of the original cancer
at a distant site, and develop-
ment of a new primary breast
cancer in the same or oppo-
site breast. Of these possibil-
ities, development of distant
metastases from the original
cancer is the most feared, as
it is generally a highly treat-
able but ultimately incurable
illness. A baffling feature is
that the time course of distant
recurrence is unpredictable;
although some patients sus-
tain a recurrence within the
first few years after diagnosis,
others suffer such an event
many years or even decades
after initial diagnosis. Efforts
to bring clarity to our under-
standing clinically have led to
the identification of prognostic
factors (those factors, like axillary lymph
node involvement and tumor size, that
predict the natural history of the breast
cancer in the absence of treatment), and
predictive factors (those factors, like
expression of estrogen receptor α, prog-
esterone receptor, and HER-2/neu pro-
teins, that predict response to a specific
treatment) (Cianfrocca and Goldstein,
2004). Although useful for counseling in
the clinic, these factors shed less light
than we might like on the underlying
mechanisms for recurrence.
In this issue of Cancer Cell, Moody
et al. (2005) tackle the vexing question of
mechanisms for breast cancer re-
currence using a doxycycline-inducible
bitransgenic mouse model for HER-
2/neu induced mammary carcinogene-
sis. Doxycycline induction of HER-2/neu
expression commonly led to develop-
ment of invasive mammary adenocarci-
nomas. Doxycycline withdrawal then
resulted in initial regression in 97% of
tumors, but over a one-year observation
period, 86% of animals developed recur-
rent tumors in the absence of doxycy-
cline. In a rigorous set of studies, the
investigators show that: (1) these are
true recurrences of preexisting disease
rather than de novo tumors, (2) recur-
rences occur independent of HER-2/neu
expression, (3) recurrent tumors demon-
strate an altered morphology suggestive
of an epithelial-to-mesenchymal transi-
tion (EMT), and (4) upregulation of
expression of the zinc finger transcrip-
tion factor, Snail, a key regulator of EMT
in other model systems, appears to play
a causative role. In a creative application
of in silico translational science, Moody
et al. (2005) queried four published data
sets of expression microarrays of prima-
ry human breast cancers about the rela-
tionship between Snail expression and
clinical outcomes and suggest that Snail
expression predicts poorer
relapse-free survival inde-
pendently of other prognostic
markers.
How should we view
these results? Certainly they
are biologically plausible. The
Snail family of zinc-finger
transcription factors plays a
central role in mesoderm for-
mation and promotion of cell
motion across species. Key to
this discussion, Snail super-
family members contribute to
phenomena such as the EMT,
a means by which epithelial
cells from one region can dis-
sociate and migrate to a new
location (Nieto, 2002). This
process is fundamental to
both normal development 
and malignant progression.
Functionally, Snail is known to
repress E-cadherin, desmo-
plakin, muc-1, and cytokeratin
18, either directly or indirectly,
while its expression is associ-
ated with enhanced vimentin
and fibronectin expression. Recently,
brisk progress has been made in under-
standing how Snail itself is regulated and
how it mediates transcriptional repres-
sion of targets like E-cadherin (Figure 1).
Indeed, it appears that Snail is located at
the hub of multiple signaling pathways
leading to EMT (Figure 1). Snail is direct-
ly induced by TGFβ1 and RAS, a process
dependent on both MAPK and PI3K
activities (Peinado et al., 2003). Two
members of the lysyl-oxidase gene fami-
ly, LOXL-2 and -3, stabilize Snail, and
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Mechanisms for breast cancer recurrence and metastases are poorly understood. New evidence from a transgenic mouse
mammary tumor model suggests that the transcriptional repressor, Snail, may play a role in recurrence by downregulating
E-cadherin and inducing an epithelial-to-mesenchymal transition. Preliminary information from expression microarray data
sets from primary human breast cancers suggests that high levels of Snail are correlated with poor clinical outcome for
women with early breast cancer. The identification of a molecular pathway involved in mammary tumor recurrence in a
mouse model offers both opportunity and challenge to confirm, extend, and exploit these findings in the clinic.
Figure 1. The central role of Snail in epithelial-to-mesenchymal transition
Snail is situated at the hub of multiple pathways leading to epithelial-
to-mesenchymal transition (EMT). A zinc finger-containing transcrip-
tion factor, Snail represses E-cadherin expression and mediates EMT
transition in mouse and human cells. In turn, multiple signal transduc-
tion pathways regulate Snail expression.
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functionally cooperate with Snail to down-
regulate E-cadherin expression (Peinado
et al., 2005). Highlighting the importance
of the microenvironment, expression of
the stromal matrix metalloproteinase
MMP-3, through generation of Rac1b,
causes an increase in cellular reactive
oxygen species, which stimulates expres-
sion of Snail (Radisky et al. 2005). Snail’s
ability to induce EMT is also determined
by the GSKβ3 glycogen synthase kinase
that prevents Snail degradation and pro-
motes Snail localization to the nucleus
(Zhou et al., 2004). A negative regulator
of Snail expression is MTA3 (metastasis
associated gene-3), a Mi-2/NuRD his-
tone deacetylase subunit, which is
responsive to estrogen signaling (Fujita
et al. 2003). More speculatively, in
Drosophila, another inducer of the EMT,
the Twist helix-loop-helix transcription
factor, induces expression of Snail and
represses expression of E-cadherin
(Castanon and Baylies, 2002); the exis-
tence of such a connection has remained
elusive in mammals. Finally, in addition to
its effects in epithelial cells, Snail may
also play an important role in tumor stro-
mal cells. Serial analysis of gene expres-
sion showed that Snail was one of the
most abundantly expressed genes in
both tumor endothelial and epithelial cells
of human breast carcinomas, but was
undetectable in normal breast (Parker et
al., 2004).
However, there are puzzles and
challenges that remain when we consid-
er the implications of these murine stud-
ies of Moody et al. (2005) for human
breast cancer. In the lab, it is not known if
Snail expression in human breast cancer
cells leads to altered morphology or
EMT. In the clinic, in the strictest sense,
these results apply only to the scenario
of local recurrence within the operated
breast. Histologically, such recurrences
in women usually resemble the original
tumor rather than demonstrating the
morphologic transition to a spindle cell
morphology observed in the mouse
mammary cancer recurrences; whether
they might demonstrate altered expres-
sion of Snail, E-cadherin, vimentin,
fibronectin, and cytokeratin 8 in compari-
son to the original tumor is not clearly
known. Whether the Snail-associated
EMT contributes to formation of distant
metastatic deposits from the recurrent
mouse tumors or primary breast cancers
in women is also not known. Biopsy of
metastatic breast cancer is not routinely
performed, leading to a paucity of tis-
sues for this type of analysis, but spindle
cell morphology is rarely seen in those
metastatic tissues that are obtained.
Because of the long disease-free interval
that patients may enjoy, it is not always
possible to recover archived specimens
from the original cancer at time of recur-
rence for simultaneous study of primary
and metastatic lesions. Translational
breast cancer researchers are beginning
to address these limitations by consider-
ing a more routine role for biopsy of
metastatic lesions as well as rapid autop-
sy programs to acquire metastatic tis-
sues to facilitate research and ultimately
improve care. In addition, this transgenic
mouse model does not take into account
the impact of therapy on mechanisms
and patterns of recurrence. Virtually all
breast cancer recurrences at any site in
women occur in the context of previous
systemic drug administration and/or
breast radiotherapy whose impact on the
biology of the recurrence is poorly under-
stood. Finally, an important challenge is
whether the provocative but hypothesis-
generating results about Snail mRNA
expression in human breast cancers
from the microarray studies presented
here and in small studies using in 
situ hybridization published elsewhere
(Blanco et al., 2002) can be confirmed by
immunohistochemical analysis of Snail
protein expression in larger independent
tumor banks that are linked to clinical
outcomes. Only then will we understand
whether the connection between Snail,
EMT, and recurrence in the HER-2/neu
model in mice also exists in women.
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